Connect with us

Technology

SIGMA LITHIUM SIGNS INAUGURAL DEFERRED US$ 22.4 MILLION LETTER OF CREDIT EXPORT FINANCING WITH BANCO DO BRASIL

Published

on

HIGHLIGHTS

Sigma Lithium signed on July 24, 2024 a deferred US$ 22.4 million letter of credit (the “Transaction”) with Banco do Brasil. This Transaction strengthens Sigma’s commercial power, enabling it to offer 90-day “export vendor financing” to its clients at very low interest rates.The Transaction amount was calculated based on the 22,000t July 5th production and shipment at the price of 8.75% of Lithium Hydroxide quoted at LME.The Transaction represents the inaugural solution for the Company developed in tandem with Banco do Brasil to deepen Sigma Lithium’s commercial partnerships during the seasonal lithium purchase cycles.As a result of the Transaction, Sigma Lithium will gradually phase out existing trade finance lines (drawn but mostly unused in the Company’s treasury) and move from a position of receiving advance payments (at a higher cost) to providing vendor financing and widening its client base.The Transaction allows Sigma Lithium to further improve its competitive position by strengthening commercial flexibility with the goal of institutionalizing a premium for its lithium concentrate.The Company’s ability to access this category of export financing demonstrates it has achieved maturity as producer within its first year of operations.

SÃO PAULO, Brazil, July 29, 2024 /CNW/ — Sigma Lithium Corporation (“Sigma Lithium” or the “Company”) (NASDAQ: SGML, BVMF: S2GM34, TSXV: SGML), a leading global lithium producer dedicated to powering the next generation of electric vehicles with carbon neutral, socially and environmentally sustainable lithium concentrate, is pleased to announce it signed an inaugural deferred US$ 22.4 million letter of credit for export financing with Banco do Brasil at very low interest rates.

As Sigma matures as an industrial producer and demonstrates its ability to consistently deliver its Quintuple Zero Green Lithium, it gained access to access low-cost trade finance mechanisms through Banco do Brasil, available to the country’s largest industrial exporters. These agreements enhance Sigma Lithium’s commercial flexibility and market access.

As a result of the lower interest export credit lines, the Company will phase out the existing trade lines in its treasury, thus decreasing the Company’s recurring interest expenses and further improving its competitiveness.  

Ana Cabral, Co-Chair and CEO of Sigma Lithium notes, “We have reached a significant milestone in our journey as a producer, achieving the maturity to access trade financing instruments available to Brazil’s largest exporters. We are honored to be working with Banco do Brasil, the country’s largest bank, which has extended through its balance sheet in Asia highly competitive interest rates to Sigma Lithium. Banco do Brasil has a history of more than a century in fostering the development of industrial exporters in the country. With this inaugural Transaction with Sigma Lithium, one of the world’s largest producers of industrial lithium materials, Banco do Brasil strengthens its leading position in developing the Brazilian green industrialization of future facing battery materials.”

“Maintaining a consistent shipping schedule, demonstrating our product quality and low costs, as well as our ability to market to downstream battery and auto makers, has opened these additional credit opportunities for Sigma. The Transaction enhances the Company’s flexibility in how it markets its Quintuple Zero Green Lithium, ultimately helping to institutionalize a price premium that reflects its superior chemical qualities.”

ABOUT SIGMA LITHIUM

Sigma Lithium (NASDAQ: SGML, TSXV: SGML, BVMF: S2GM34) is a leading global lithium producer dedicated to powering the next generation of electric vehicle batteries with carbon neutral, socially and environmentally sustainable chemical-grade lithium concentrate.

Sigma Lithium is one of the world’s largest lithium producers with an annual production capacity of 270,000 tonnes of chemical grade lithium concentrate (36,700 LCE annually). The Company operates at the forefront of environmental and social sustainability in the EV battery materials supply chain at its Grota do Cirilo Operation in Brazil. The Company produces Quintuple Zero Green Lithium at its state-of-the-art Greentech lithium plant that delivers zero carbon lithium, produced with zero dirty power, zero potable water, zero toxic chemicals and zero tailings’ dams.

Phase 1 of the project entered commercial production in 2Q23 and has an annual capacity of 270,000 tonnes of concentrate (36,700 LCE annually).The Company has issued a Final Investment Decision formally approving construction to nearly double capacity to 520,000 tonnes of concentrate through the addition of a Phase 2 expansion of its Greentech Plant.

Please refer to the Company’s National Instrument 43-101 technical report titled “Grota do Cirilo Lithium Project Araçuaí and Itinga Regions, Minas Gerais, Brazil, Amended and Restated Technical Report” issued March 19, 2024, which was prepared for Sigma Lithium by Homero Delboni Jr., MAusIMM, Promon Engenharia; Marc-Antoine Laporte, P.Geo, SGS Canada Inc; Jarrett Quinn, P.Eng., Primero Group Americas; Porfirio Cabaleiro Rodriguez, (MEng), FAIG, GE21 Consultoria Mineral; and William van Breugel, P.Eng (the “Updated Technical Report”). The Updated Technical Report is filed on SEDAR and is also available on the Company’s website.

For more information about Sigma Lithium, visit https://www.sigmalithiumresources.com/

Sigma Lithium

LinkedIn: Sigma Lithium
Instagram: @sigmalithium
Twitter: @SigmaLithium

FORWARD-LOOKING STATEMENTS

This news release includes certain “forward-looking information” under applicable Canadian and U.S. securities legislation, including but not limited to statements relating to timing and costs related to the general business and operational outlook of the Company, the environmental footprint of tailings and positive ecosystem impact relating thereto, donation and upcycling of tailings, timing and quantities relating to tailings and Green Lithium, achievements and projections relating to the Zero Tailings strategy, achievement of ramp-up volumes, production estimates and the operational status of the Groto do Cirilo Project, and other forward-looking information. All statements that address future plans, activities, events, estimates, expectations or developments that the Company believes, expects or anticipates will or may occur is forward-looking information, including statements regarding the potential development of mineral resources and mineral reserves which may or may not occur. Forward-looking information contained herein is based on certain assumptions regarding, among other things: general economic and political conditions; the stable and supportive legislative, regulatory and community environment in Brazil; demand for lithium, including that such demand is supported by growth in the electric vehicle market; the Company’s market position and future financial and operating performance; the Company’s estimates of mineral resources and mineral reserves, including whether mineral resources will ever be developed into mineral reserves; and the Company’s ability to operate its mineral projects including that the Company will not experience any materials or equipment shortages, any labour or service provider outages or delays or any technical issues. Although management believes that the assumptions and expectations reflected in the forward-looking information are reasonable, there can be no assurance that these assumptions and expectations will prove to be correct. Forward-looking information inherently involves and is subject to risks and uncertainties, including but not limited to that the market prices for lithium may not remain at current levels; and the market for electric vehicles and other large format batteries currently has limited market share and no assurances can be given for the rate at which this market will develop, if at all, which could affect the success of the Company and its ability to develop lithium operations. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether because of new information, future events or otherwise, except as required by law. For more information on the risks, uncertainties and assumptions that could cause our actual results to differ from current expectations, please refer to the current annual information form of the Company and other public filings available under the Company’s profile at www.sedar.com.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

View original content to download multimedia:https://www.prnewswire.com/news-releases/sigma-lithium-signs-inaugural-deferred-us-22-4-million-letter-of-credit-export-financing-with-banco-do-brasil-302208290.html

SOURCE Sigma Lithium Corporation

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

New Year, New Health Insurance Changes: BuzzRx® Can Help Fill the Gap in Prescription Coverage

Published

on

By

Save Smart and Bee Healthy

FORT LAUDERDALE, Fla., Jan. 14, 2025 /PRNewswire/ — As we enter a new year, many Americans may be facing unwelcome changes to their health insurance plans, including the removal or reduction of prescription medications from their coverage. With health insurance policies adjusting annually, BuzzRx, a free prescription savings service that allows users to instantly find the lowest price on their medication at pharmacies nationwide, is stepping up to help fill the gap by providing access to affordable prescription medications through exclusive discounts at over 60,000 participating pharmacies nationwide.

The Start of the Year Brings Health Insurance Changes—and Increased Costs

Each year, millions of Americans experience shifts in their health insurance coverage. One of the most common changes is that their prescription medications may no longer be covered. According to the latest data from the Kaiser Family Foundation, nearly 1 in 5 (approximately 23%) individuals with private health insurance face interruptions in their prescription drug coverage once their new policy takes effect. These changes can result in out-of-pocket expenses that are financially burdensome and potentially harmful to individuals’ health.

“Health insurance companies often update their formularies, dropping certain medications or shifting drugs to higher tiers that are not covered as fully,” states Matthew Herfield, Co-Founder and CEO of BuzzRx. “For those who depend on regular medications, these changes can pose a significant financial hardship. BuzzRx is here to help ease that burden by offering discounted prices on prescriptions, regardless of whether your medication is covered by insurance.”

How BuzzRx Can Help You Save on Prescription Medications

BuzzRx offers an affordable and easy way to get the medications you need, even if your insurance no longer covers them. With BuzzRx, users can access exclusive discounts at over 60,000 pharmacies nationwide, including major chains and independent pharmacies.

No insurance? No problem: BuzzRx provides savings on medications for those without insurance or those whose insurance doesn’t cover certain medications.Instant Savings: BuzzRx can save you up to 80% off on prescriptions immediately. Simply show your BuzzRx coupon for your medication at the pharmacy to receive your discount.Broad Coverage: BuzzRx offers discounts on a wide range of medications, including generic and brand-name drugs.Simple & Free: Signing up for BuzzRx is quick and free—no hidden fees, no complicated paperwork, and no waiting periods.

In addition, BuzzRx’s BeeKind program gives back to four nonprofit partners every time someone saves, ensuring that every discount used can help others in need.

The Impact of Losing Prescription Coverage

Losing coverage for critical medications can have far-reaching consequences. According to a study by the National Public Radio (NPR), as many as 33% of Americans report not filling prescriptions due to high out-of-pocket costs. When health insurance no longer covers necessary medications, many are forced to make difficult choices between buying medications or paying for other essential needs.

It’s easy to start saving with BuzzRx. Simply visit buzzrx.com or download the BuzzRx app to sign up for a free BuzzRx account and begin accessing prescription discounts immediately.

About BuzzRx
BuzzRx is a free prescription discount service that allows users to find the lowest price on their medication instantly at over 60,000 pharmacies nationwide. The website and free mobile app promote drug transparency by allowing users to compare discounted prices across pharmacy chains, helping reduce out-of-pocket costs and sticker shock at the counter. Since 2021, BuzzRx has helped over 10 million people in the U.S. save up to 80% on their medications, resulting in over $2 billion saved. BuzzRx also supports its nonprofit partners year-round, donating over 10 million. For more information, visit BuzzRx.com or download the free mobile app on iOS and Android.

Press Contact
Press@BuzzRx.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/new-year-new-health-insurance-changes-buzzrx-can-help-fill-the-gap-in-prescription-coverage-302349788.html

SOURCE BuzzRx

Continue Reading

Technology

USTA President Brian Hainline, MD Joins Tennis Social AI as Chief Innovation & Health Officer

Published

on

By

NEW YORK, Jan. 14, 2025 /PRNewswire/ — Tennis Social AI proudly announces Brian Hainline, MD as its Chief Innovation and Health Officer, marking a transformative step in its mission to redefine tennis and racquet sports.

“Tennis Social AI addresses a critical gap in bringing tennis to the people.” – Brian Hainline, MD

Brian, former President of the USTA and the first Chief Medical Officer of the NCAA, brings decades of leadership and expertise at the intersection of health, sports, and innovation. A Clinical Professor of Neurology at NYU Grossman School of Medicine, Brian has been a vocal advocate for tennis as the healthiest sport in the world. His role at Tennis Social AI will focus on driving cutting-edge initiatives to broaden the sport’s accessibility, unlock its health benefits, and integrate technology to elevate the player experience.

“Tennis is the healthiest sport on the planet – but that only matters if tennis is accessible to individuals and communities from all cultures, all ages, and all abilities,” Brian shared. “Tennis Social AI addresses a critical gap in bringing tennis to the people – tennis that is fun, engaging, and a platform for developmental success. I feel privileged to be part of this journey.”

At Tennis Social AI, the mission is to make tennis more social, fun, and accessible to everyone, regardless of age, ability, or skill level. Brian’s addition to the team comes as the company prepares for its first installations and public launch in early 2025.

Rooted in tennis, Tennis Social AI’s proprietary technology also holds the potential to revolutionize other racquet sports, including pickleball and padel. This versatility positions the company as a leader in racquet sports simulation.

2025 promises to redefine racquet sports innovation. Tennis Social AI will blend entertainment, fitness, and training, paving the way for a future where the sport inspires and stays accessible to all.

For more information on brand opportunities and pre-sales, contact: Steven McClendon at steven@tennissocial.ai / Tyler Kelly at Tyler@tennissocial.ai or visit https://tennissocial.ai/

View original content:https://www.prnewswire.com/news-releases/usta-president-brian-hainline-md-joins-tennis-social-ai-as-chief-innovation–health-officer-302349458.html

SOURCE Tennis Social AI

Continue Reading

Technology

Tyber Medical, Intech and Resolve Surgical Technologies combine to form a next-generation solutions provider to the Medical Device industry

Published

on

By

LONDON, Jan. 14, 2025 /PRNewswire/ — Montagu announced today its intention to create a world-leading medical devices supplier by supporting the merger of Tyber Medical, Intech and Resolve Surgical Technologies (“Resolve”).

As part of the transaction, Montagu entered into a definitive agreement to acquire Tyber Medical, an innovative medical device company providing private label development and manufacturing services to med-tech Original Equipment Manufacturers (OEMs). Subject to customary regulatory approvals and closing conditions, Tyber Medical will be combined with Montagu’s existing investments in Resolve, a leading provider of contract device design, manufacturing, and lifecycle management services, as well as in Intech, a leader in the co-development and manufacturing of complex orthopaedic surgical devices.

The combined entity will offer a unique mix of proprietary market-cleared technologies, and development and manufacturing scale, that will enable its OEM customers to achieve unmatched speed to market and improve the resiliency and effectiveness of their supply chain. At the time of the merger, the platform will be a leading contract supplier of systems for Spine, Trauma, Extremities, Sports Medicine and Enabling Technologies, with plans to expand its pioneering innovation-led model into additional markets. The planned merger will support accelerated innovation and help improve standards of care for patients globally.

Jeff Tyber, Founder and CEO at Tyber Medical said: “Tyber Medical’s proven track record of successful global launches, averaging 12 months from signing to launch, has revolutionized how our partners expand their portfolios and adapt to the evolving market dynamics. This strategic combination brings together the size, scale, and expertise of Intech, along with Resolve’s deep knowledge in the Spine and Cardiothoracic fields. We are delighted to be partnering with Montagu, a leading investment firm in the private label OEM sector, and we share their vision of creating an industry champion.”

“This unique combination represents a significant milestone, enhancing our ability to serve medical technology companies worldwide,” said Laurent Pruvost, President and CEO of Intech. “By combining Intech’s global manufacturing footprint and know-how with Resolve and Tyber’s tailored solutions, we will establish ourselves as the undisputed partner of choice in the industry.”

Megan Osorio, President and CEO of Resolve said: “Bringing innovation to market with speed and quality is of the utmost importance to our OEM customers. Joining forces will increase our ability to support their growth across the full range of orthopaedic implants & instruments by bringing the deep experience of our respective teams and scale of our manufacturing footprint together.”

Adrien Sassi, Partner at Montagu said: “Montagu is proud to support the creation of this world-class medical device platform. The three organisations share similar passion and focus on delivering innovative, high-quality, reliable solutions to OEM customers, surgeons, and patients. We look forward to partnering with Jeff Tyber and his talented team, as well as extending our successful collaboration with Intech and Resolve.”

Houlihan Lokey and Dechert LLP, respectively, acted as exclusive financial advisor and legal advisor to Tyber Medical. Weil Gotshal & Manges acted as legal advisor to Montagu, Intech and Resolve.

Media enquiries

Greenbrook: James Madsen and Cecilie Oerting
+44 20 7952 2000 | montagu@greenbrookadvisory.com

About Intech

Intech is a global leader in the manufacturing of orthopaedic devices and mission-critical components. With facilities in the USA, Europe, and Asia-Pacific, the group excels in producing surgical implants, instruments, cutting tools, handles, and sterilization containers. With innovation at heart, Intech is at the forefront of contract-design and contract-manufacturing in the field of Orthopaedics and Healthcare. Intech is also home to SMADE, its IoMT division that offers smart tracking of geolocation, sterilisation cycles, and usage of surgical containers on the field. For more information, visit https://intech-medical.com/.

About Resolve Surgical Technologies

Resolve Surgical Technologies is an industry-leading private label OEM that designs, develops and manufactures metal and polymer implants and instruments serving the orthopaedics, spine and cardiothoracic markets. Originally founded in 1992 as Pioneer Surgical Technology, Inc. and later known as the Metals division of RTI Surgical, Resolve became known for their innovative designs and engineering expertise. Today, Resolve Surgical focuses on creating value as an extension of our OEM partners’ teams to deliver innovation, accelerate speed to revenue and drive lifecycle management with robust quality and regulatory support. For more information, visit www.resolvesurg.com.

About Tyber Medical LLC

Tyber Medical LLC is a leading orthopaedic device manufacturer providing rapid access to FDA-cleared and CE-marked, private label, portfolio-enhancing regulatory-approved orthopaedic implants for the spinal, extremity, and trauma markets. Since its founding in 2012, the company has released more than 50 spine, extremity, and trauma systems. Tyber Medical aims to develop and utilize differentiated bioengineered technologies, including surface treatments and coatings, to advance orthopaedic science. For more information, visit https://tybermedical.com/.

About Montagu

Montagu is a leading mid-market private equity firm, committed to finding and growing businesses that make the world work. Focussing on businesses with a must-have product or service in a structurally growing marketplace, Montagu brings proven growth capabilities to help companies achieve their ambitions and unlock their full potential. Montagu specialises in carve-out and other first time buyout investments and has deep expertise in five priority sectors: Healthcare, Financial Sector Services, Critical Data, Digital Infrastructure and Education. ESG forms an integral part of its strategy, and its commitment to responsible investment is fully integrated into its investment and value-creation process. Montagu partners with companies with enterprise values between €200 million and €1 billion and has €12bn assets under management. For additional information on Montagu, visit www.montagu.com

 

 

View original content:https://www.prnewswire.co.uk/news-releases/tyber-medical-intech-and-resolve-surgical-technologies-combine-to-form-a-next-generation-solutions-provider-to-the-medical-device-industry-302350537.html

Continue Reading

Trending